JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thomas, D.
Right arrow Articles by Kiehn, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thomas, D.
Right arrow Articles by Kiehn, J.

J Biol Chem, Vol. 274, Issue 39, 27457-27462, September 24, 1999


Deletion of Protein Kinase A Phosphorylation Sites in the HERG Potassium Channel Inhibits Activation Shift by Protein Kinase A*

Dierk ThomasDagger , Wei ZhangDagger , Christoph A. Karle, Sven Kathöfer, Wolfgang Schöls, Wolfgang Kübler, and Johann Kiehn§

From the Department of Cardiology, Medical University Hospital Heidelberg, Bergheimerstrasse 58, D-69115 Heidelberg, Germany

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We investigated the role of protein kinase A (PKA) in regulation of the human ether-a-go-go-related gene (HERG) potassium channel activation. HERG clones with single mutations destroying one of four consensus PKA phosphorylation sites (S283A, S890A, T895A, S1137A), as well as one clone carrying all mutations with no PKA phosphorylation sites (HERG 4M) were constructed. These clones were expressed heterologously in Xenopus oocytes, and HERG potassium currents were measured with the two microelectrode voltage clamp technique. Application of the cAMP-specific phosphodiesterase (PDE IV) inhibitor Ro-20-1724 (100 µM), which results in an increased cAMP level and PKA stimulation, induced a reduction of HERG wild type outward currents by 19.1% due to a shift in the activation curve of 12.4 mV. When 100 µM Ro-20-1724 was applied to the HERG 4M channel, missing all PKA sites, there was no significant shift in the activation curve, and the current amplitude was not reduced. Furthermore, the adenylate cyclase activator forskolin that leads to PKA activation (400 µM, 60 min), shifted HERG wild type channel activation by 14.1 mV and reduced currents by 39.9%, whereas HERG 4M channels showed only a small shift of 4.3 mV and a weaker current reduction of 22.3%. We conclude that PKA regulates HERG channel activation, and direct phosphorylation of the HERG channel protein has a functional role that may be important in regulation of cardiac repolarization.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In cardiac myocytes, repolarization of the action potential is produced by different potassium currents (1). Activation of the rapid component of the delayed rectifier potassium current, IKr,1 initiates repolarization and terminates the plateau phase of the cardiac action potential. The human ether-a-go-go-related gene (HERG) (2) encodes the voltage-gated potassium channel underlying IKr. This has been demonstrated in macroscopic current measurements (3, 4) and single channel measurements (5). HERG channels are one primary target for the pharmacological management of arrhythmias with class III antiarrhythmic drugs: IKr is blocked and the cardiac action potential is prolonged (5-7). Mutations in HERG produce chromosome 7-linked congenital long QT syndrome (LQT2) (3). These mutations are associated with delayed cardiac repolarization, prolonged electrocardiographic QT intervals (8), and a high risk for the development of ventricular "torsade de pointes" arrhythmias and sudden cardiac death (9).

Cyclic AMP-dependent protein kinase (PKA) is a key enzyme for numerous regulatory processes in almost all types of cells. It has been demonstrated that PKA regulates ion channels in native tissue (10). PKA is a serine/threonine kinase that can be stimulated by extracellular signals that elevate intracellular cAMP concentrations. cAMP binds to the regulatory subunit of the enzyme, which leads to dissociation of regulatory and catalytic subunits. The catalytic subunit phosphorylates the substrate at its specific phosphorylation sites. The substrate may either be the effector protein or another protein that mediates the effect. Increased cAMP concentrations can be obtained experimentally with the adenylate cyclase activator forskolin (11) and with the selective cAMP-specific phosphodiesterase (PDE IV) inhibitor Ro-20-1724 (12).

Recently, we have demonstrated that PKA is involved in the regulation of IKr in guinea pig cardiac myocytes and HERG channels expressed heterologously in Xenopus oocytes (13). Incubation of the cells with the phorbol ester phorbol 12-myristate 13-acetate (PMA) leads to a HERG current reduction due to a shift in the activation curve that is mediated mainly by PKA. To investigate the biochemical pathways of this regulation process in more detail, we generated single mutations of all four PKA-specific phosphorylation sites in HERG, combined all of them, and expressed the resulting channel proteins in Xenopus oocytes. Because all enzymes involved in the PKA cascade are present endogenously in Xenopus oocytes, we could use indirect protein kinase A activators and inhibitors to study the role of PKA in HERG channel regulation.

Our findings show that direct phosphorylation of the channel protein by PKA is involved in the regulation of HERG channel activation, and the PKA-mediated part of the shift in the HERG activation curve can be abolished by mutating all PKA-specific phosphorylation sites in the HERG channel protein.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Solutions and Drug Administration-- Voltage clamp measurements of Xenopus oocytes were performed in a low K+ solution containing (in mM) 5 KCl, 100 NaCl, 1.5 CaCl2, 2 MgCl2, and 10 HEPES (pH 7.3). Current and voltage electrodes were filled with 3 M KCl solution.

Forskolin (Calbiochem) and Ro-20-1724 (Calbiochem) were dissolved in Me2SO to a stock solution of 100 mM and stored at -20 °C. Phorbol-12,13-didecanoate (Calbiochem) was dissolved in Me2SO to a stock solution of 10 mM and stored at -20 °C. On the day of experiments, aliquots of the stock solution were diluted to the desired concentration with the bath solution. All measurements were carried out at room temperature (20 °C).

Electrophysiology and Data Analysis-- The two-microelectrode voltage-clamp configuration was used to record currents from Xenopus laevis oocytes. Microelectrodes had tip resistances ranging from 1 to 5 megaohms. Data were low-pass filtered at 1-2 kHz (-3 dB, four-pole Bessel filter) before digitalization at 5-10 kHz. Recordings were performed using a commercially available amplifier (Warner OC-725A, Warner Instruments, Hamden, CT) and Pclamp software (Axon Instruments, Foster City, CA) for data acquisition and analysis. No leak subtraction was done during the experiments. The recording chamber was continually perfused. Activation curves were fitted with a Boltzmann distribution: G(V) = Gmax/(1 - exp[(V1/2 - V)/k]), where V is the test pulse potential, V1/2 is the half-maximal activation potential, and k is the slope of the activation curve. Statistical data are expressed as mean ± S.D. (n = number of experiments performed). We used paired and unpaired Student's t test to compare the statistical significance of the results: p < 0.05 was considered to be statistically significant.

Site-directed Mutagenesis-- The HERG wild type (HERG WT) clone (3) was a gift from M. T. Keating (GenBankTM accession number hs04270), which contains the HERG potassium channel coding region downstream the SP6 polymerase promotor. By use of computer analysis with the program HUSAR PROSITE, we searched for consensus PKA phosphorylation sites with the amino acid sequence Arg-Lys-(2)-Xaa-Ser-Thr, where (2) means Arg-Arg and Lys-Lys are also allowed. The program identified four sites. The serine or threonine residues of the PKA phosphorylation sites (Ser-283, Ser-890, Thr-895, Ser-1137) were replaced with the nonphosphorylatable alanine to eliminate PKA-mediated phosphorylation at this position. This resulted in the mutated channels HERG S283A, HERG S890A, HERG T895A, HERG S1137A) The mutations were generated with polymerase chain reaction by mutagenesis on the double-stranded plasmid using the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA). The polymerase chain reaction products between unique anchor sites were sequenced (MWG-Biotech, Ebersberg, Germany), and fragments between these unique restriction sites were cut out using the following combinations of restriction enzymes: BstEII (1137) and NcoI (668) for HERG S283A; FseI (2779) and XhoI (2107) for HERG S890A and HERG T895A; BamHI (3532) and FseI (2779) for HERG S1137A. The mutated fragments were subcloned into the original HERG plasmid and sequenced again.

The HERG 4M clone (combination of all four mutations) was generated by introducing mutation S890A into the T895A clone as described above, generating HERG S890A,T895A. Then the restriction fragments containing mutations S283A and S1137A were subcloned into HERG S890A,T895A. Finally, cDNA of HERG 4M was verified by DNA sequencing.

Expression of HERG Channels in Xenopus Oocytes-- Complementary RNA was prepared from the corresponding cDNA (HERG WT, HERG S283A, HERG S890A, HERG T895A, HERG S1137A, HERG 4M) in the pSP64 transcription vector (Promega, Madison, WI) with the mMESSAGE mMACHINE in vitro transcription kit (Ambion, Austin, TX) by use of SP6 polymerase after linearization with EcoRI (Roche Molecular Biochemicals). Injection of RNA (50-500 ng/µl) into stage V and VI defolliculated oocytes was performed by using a Nanoject automatic injector (Drummond, Broomall, PA). The volume of injected cRNA solution was 46 nl/oocyte, and measurements were made 2-10 days after injection.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Expression of HERG Channels with Deleted Consensus Phosphorylation Sites for PKA-- We performed site-directed mutagenesis of HERG to generate mutated channels that lack consensus PKA phosphorylation sites (HERG S283A, HERG S890A, HERG T895A, HERG S1137A; and in combination HERG 4M, see Fig. 1) and expressed these mutant channels in Xenopus oocytes. All clones generated in this study resulted in functional potassium channels with current kinetics similar to those of HERG WT.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 1.   Hypothetical membrane folding model for the HERG potassium channel. The amino and carboxyl termini and the six membrane-spanning domains are indicated. The locations of four putative PKA-specific phosphorylation sites and mutations generated in this study are illustrated. For simplicity, only the mutated amino acids are shown.

HERG Wild Type Channel Activation Curve Was Shifted by Increasing cAMP Levels via Inhibition of the PDE IV-- To investigate the effects of the PDE IV inhibitor Ro-20-1724 (IC50 = 2.2 µM) on HERG potassium channels, we measured currents using a two-step protocol (see Fig. 2A). A variable first step (test pulse) was applied at different potentials from -80 mV to +80 mV (increment 10 mV) for 0.4 s and a second step at -120 mV to measure inward tail currents. The holding potential was -80 mV in all experiments performed in this study. The tail current amplitude depends on the preceding test pulse and is a measure of channel activation. The normalized tail current amplitude was inverted and displayed as a function of the preceding test pulse potential, which results in the activation curve. In the control currents, the voltage for half-maximal activation V1/2 was -4.3 mV (Fig. 2, A and C). When 100 µM Ro-20-1724 was applied into the bath for 30 min (Fig. 2B), the activation curve was shifted by 14.0 mV to 9.7 mV (Fig. 2C). The average shift in five experiments was 12.4 ± 3.2 mV. This was statistically significant. We used an additional protocol that evokes outward tail currents as shown in Fig. 2D. The variable test pulse from -80 to 80 mV (increment 10 mV) for 0.4 s was followed by a constant return pulse to -60 mV (0.4 s). The control HERG current had an activation threshold of -40 mV, then the current amplitude reached a maximum at 0 mV and decreased at test pulse potentials from 20 to 70 mV because of inward rectification that is characteristic to this channel (3, 5, 14). Typical current traces are shown in Fig. 2D (control measurements) and Fig. 2E (after application of 100 µM Ro-20-1724 into the bath for 30 min). The maximum outward current amplitude during the test pulse was reduced significantly by 19.1 ± 12.8% (n = 5). Fig. 2F displays the current amplitude during the test pulse as a function of the test pulse potential (control measurement and after incubation with 100 µM Ro-20-1724 for 30 min).


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 2.   Stimulation of PKA by the phosphodiesterase IV inhibitor Ro-20-1724 causes a shift of HERG WT activation curve and suppression of outward current. Control measurements (panels A and D) and the effect of 100 µM Ro-20-1724 after 30 min (panels B and E) in the same oocyte. Panel C shows activation curves, i.e. the normalized inverted peak tail current amplitude as a function of the test pulse potential during the first step of the inward tail protocol (panels A and B). Ro-20-1724 shifts the activation curve by 14.0 mV. Panel F shows the current amplitude at the end of the test pulse of the outward tail protocol (in D and E) as a function of the test pulse potential in control and after stimulation with Ro-20-1724. The maximum current amplitude at 0 mV is reduced in the measurements with Ro-20-1724 by 30.3%. Inward tail protocol in panels A and B: holding potential -80 mV, test pulse -80 to 80 mV (400 ms) in 10 mV increments, return pulse constant -120 mV (400 ms). Outward tail protocol in panel D and E: holding potential -80 mV, test pulse -80 to 80 mV (400 ms) in 10 mV increments, return pulse constant -60 mV (400 ms). Bath: 5 mM K+.

Deletion of Phosphorylation Sites Inhibits the Activation Shift Caused by PDE IV Inhibition in HERG 4M-- We mutated all four consensus PKA phosphorylation sites in the HERG channel protein (HERG 4M). The current kinetics of the HERG 4M clone was almost identical to the wild type HERG channel current kinetics (compare Figs. 3, A and D with Fig. 2, A and D), but the half-maximal activation voltage obtained during control measurements was shifted toward more negative potentials (Fig. 3C). The average V1/2 of HERG 4M during control experiments was -16.4 ± 1.6 mV (n = 6) (HERG wild type gave -4.7 ± 1.5 mV (n = 3)). In contrast to HERG WT, addition of 100 µM Ro-20-1724 caused virtually no change of current properties in HERG 4M after 30 min of perfusion (Fig. 3, D and E). V1/2 was only shifted by 3.8 ± 1.7 mV to -12.6 ± 2.4 mV (n = 6) (Fig. 3C and Fig. 6A), and there was no significant current reduction ((Delta I = +2.8 ± 8.1% (n = 6) (Fig. 3F)). Thus, direct phosphorylation of HERG WT channels at its PKA phosphorylation sites is responsible for the activation shift induced by PKA.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 3.   Stimulation of PKA with the phosphodiesterase inhibitor Ro-20-1724 causes no significant effects in the HERG 4M channel, where all PKA phosphorylation sites were mutated to nonphosphorylatable alanines. Control measurements of HERG 4M (panels A and D) and the effect of 100 µM Ro-20-1724 (panels B and E) after 30 min in the same oocyte. The shift of the activation curve was not significant (3.7 mV, panel C), and there was no current reduction (+1.4%, panel F) due to the lack of functional PKA phosphorylation sites. Protocols and plots were identical to those in Fig. 2. Bath: 5 mM K+.

Elevation of cAMP Levels by Forskolin Leads to a Shift of the HERG Channel Activation Curve-- To further elucidate the role of protein kinase A in the HERG activation process in a different experimental approach, we applied forskolin to the Xenopus oocytes expressing HERG WT channels. Forskolin is an adenylate cyclase activator (EC50 = 4.0 µM) that increases intracellular cAMP levels and subsequently stimulates PKA. After having obtained the control measurements (Fig. 4, A and D), forskolin (400 µM) was perfused into the bath for 60 min. The resulting current traces are shown in Fig. 4, B and E. Apparently, the activation curve was shifted, and the maximum outward current during test pulses was reduced. In four experiments V1/2 was shifted significantly by 14.1 ± 4.2 mV from 1.6 ± 2.0 mV to 15.7 ± 4.9 mV. Currents were reduced by 39.9 ± 13.3% (n = 4). Given the elevation of cAMP levels inside the oocyte by forskolin, this demonstrates indirectly that PKA is a key enzyme for the described activation shift.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 4.   Forskolin (400 µM), an adenylate cyclase activator that leads to PKA stimulation, shifts the activation curve in HERG WT currents. Original currents obtained from the same oocyte before (panels A and D) and after exposure to 400 µM forskolin (60 min; panels B and E). The resulting activation curve is shifted by 13.6 mV (panel C). Maximum outward current amplitude (measured at the end of the test pulse in panels D and E) was reduced by 59.0%. Protocols and plots were identical to those shown in Fig. 2. Bath: 5 mM K+.

Elevation of cAMP Levels by Forskolin Does not Shift the Activation Curve of HERG 4M Channels-- To address the question whether direct phosphorylation of the channel protein is involved in the cascade of activation shift induced by forskolin, we incubated HERG 4M with 0.4 mM forskolin. 60 min after having recorded control current traces (Fig. 5, A and D), we found only a small shift in the activation curve of 4.3 ± 1.6 mV from -16.6 ± 0.4 mV to -12.3 ± 2.1 mV (n = 3, Fig. 5C). This shift was significantly different from the effect of forskolin on HERG wild type channels. Currents during test pulses were also reduced but to a smaller extent (-22.3 ± 26.2% (n = 3), Fig. 5, D-F), compared with HERG wild type (-39.9%). Thus the presence of functional phosphorylation sites regulates the PKA-mediated activation shift in HERG channels by forskolin.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 5.   Mutation of the PKA phosphorylation sites inhibits the shift of activation curve by forskolin in the HERG 4M channel. Panels A and D show typical control measurements of HERG 4M currents in different protocols. The resulting currents (same oocyte) after perfusion with 400 µM forskolin (60 min) are shown in panels B and E. The shift of activation curve by forskolin was 3.1 mV (panel C), reduction of the current amplitude at the end of the test pulse was 43.2% (panel F). Protocols and plots were identical to those shown in Fig. 2. Bath: 5 mM K+.

HERG 4M Channel Baseline Activation Curves Are -10.1 mV More Negative Than HERG Wild Type Activation Curves-- Based on the results described above, it is likely that PKA-mediated phosphorylation is involved in HERG activation. This hypothesis is further strengthened by the observation that the baseline midpoint of the activation curve of HERG 4M was -14.8 ± 2.2 mV (n = 9), whereas the HERG WT baseline midpoint was -4.7 ± 1.5 mV (n = 3, Fig. 6). This difference of -10.1 mV was statistically significant. The difference in the activation curves becomes even greater when we compare the activation curves values under stimulation of PKA with the phosphodiesterase inhibitor Ro-20-1724. Under this condition, the HERG 4M has a half-maximal activation voltage of -12.6 ± 2.4 mV (n = 6), whereas HERG wild type has 9.7 ± 3.2 mV (n = 5). This results in a difference of 22.3 mV between HERG 4M and HERG wild type (Fig. 6A). Some of the clones carrying single mutations showed a tendency toward more negative potentials as well (T895A, S283A, and especially S890A) (Fig. 6B). The values were V1/2= -5.9 ± 2.4 mV for T895A (n = 9), V1/2= -6.0 ± 3.0 mV for S283A (n = 6), V1/2= -8.0 ± 4.8 mV for S890A (n = 6), and V1/2= -2.6 ± 1.9 mV for S1137A (n = 7).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 6.   A, activation curves of HERG WT and HERG 4M during control measurements and after incubation with 100 µM Ro-20-1724 for 30 min in a typical experiment. Inhibition of the phosphodiesterase IV by Ro-20-1724 causes a shift of the activation curve in HERG WT channels by 14.0 mV, whereas in HERG 4M channels there was no significant shift (3.7 mV). Note that the baseline activation curve is more negative in HERG 4M than in HERG WT channels. B, graphical overlay of the channel baseline activation curves of HERG, HERG 4M, and the four single mutations of HERG. Mean values of control activation curves for each channel type resulting from 3 to 9 oocytes measurements are shown. Symbols represent mean activation curves for HERG WT (black-square), HERG S283A (black-triangle), HERG S890A (black-down-triangle ), HERG T895A (black-diamond ), HERG S1137A +, HERG 4M ().


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

This study demonstrates that HERG potassium channel activation is regulated by direct phosphorylation of the HERG protein. This has been shown by mutating all four consensus PKA phosphorylation sites in the HERG protein (resulting in the HERG 4M channel) and analyzing the electrophysiological effects of PKA stimulation by adding Ro-20-1724, an inhibitor of the PDE IV, or adding the adenylate cyclase activator forskolin. Our results demonstrated that the HERG wild type activation curve was shifted and the repolarizing HERG current amplitude was reduced by protein kinase A, whereas in the HERG 4M channel these effects were virtually absent. Because all PKA sites are mutated in the HERG 4M channel, we conclude that PKA produces these electrophysiological effects by direct phosphorylation of the channel protein.

Regulation of HERG channels by PKA has been found recently in another expression system as well. Palma et al. (15) could demonstrate that stimulation of PKA reduces HERG currents in HERG-transfected cultural cells. In isolated guinea pig cardiomyocytes, the rapid component of the delayed rectifier potassium current, IKr, that is produced by the HERG potassium channel was decreased by stimulating protein kinases, presumably PKA (13). Therefore regulation of HERG channels by PKA may be of physiological relevance.

The baseline midpoint of the activation curve was -4.7 mV for HERG WT and -14.8 mV for HERG 4M (Fig. 6A). This difference in the baseline activation curves indicates that the positions of the mutations and its phosphorylation by PKA are crucial for activation. Even more so, because the difference in activation after stimulation of PKA was higher (22mV) (Fig. 6A). There are two possible explanations for the difference in the baseline half-maximal activation voltage between HERG WT and HERG 4M channels. Either mutating the serines or threonines to alanines causes this effect, but more likely the naturally occurring higher phosphorylation occupancy of HERG WT compared with HERG 4M induces this baseline shift. All four mutations contribute to the baseline shift, because single mutations shift the activation curve to a smaller extent compared with HERG 4M (Fig. 6B).

In a previous study (13), we demonstrated that the phorbol ester PMA produces a stronger PKA-dependent shift in the activation kinetics of HERG channels (37 mV) compared with the shift by Ro-20-1724 (14.0 mV) or forskolin (14.1 mV). PMA is a very potent but not specific compound. It is known to be an activator of protein kinase C and other protein kinases including PKA, and many of its effects are not fully understood. There is clear evidence that direct activation of protein kinase C is not involved in shifting the activation curve of HERG channels, because the very similar phorbol ester, phorbol-12,13-didecanoate, known to activate PKC (16), does not produce any shift (data not shown). Furthermore, experiments with the direct and very specific PKC activator 1-stearoyl-2-arachidonyl-glycerol support these results as well, because they produced no shift (13). In this study, we exclusively investigated PKA-specific effects particularly with PKA pathway-specific compounds, such as forskolin or Ro-20-1724. Nevertheless there are possibly other factors as well mediating the PMA-induced shift that cannot be determined at this point.

Some clinical conditions might reflect the physiological significance of our findings. Under beta -adrenergic stimulation (17-19) or in pathophysiological situations like sepsis (20-23) and ischemia (24), the cAMP level in cardiac cells is elevated. At the same time these conditions are associated with a high incidence of cardiac arrhythmias. Also, patients with congenital long QT syndrome typically develop "torsade de pointes" arrhythmias under emotional or physical stress when cAMP levels are elevated (25, 26). Finally arrhythmias are a common side effect during the therapeutical use of phosphodiesterase inhibitors (27) in situations like chronic heart failure (28) or cardiogenic shock. Our results demonstrate a link between the cAMP-PKA-system and the repolarizing HERG potassium current. The PKA-induced phosphorylation of HERG and changes in repolarization described in this study may be a crucial link in arrhythmogenesis. Thus, this regulatory process may be a pharmacological target for future therapeutic approaches in antiarrhythmic therapy.

    ACKNOWLEDGEMENTS

We thank Dr. M. T. Keating for providing the HERG clone, and we gratefully acknowledge the technical support of K. Güth, S. Kadel, and S. Lück.

    FOOTNOTES

* This work was supported by a grant from the Deutsche Forschungsgemeinschaft project A/11 (to J. K.) within the Sonderforschungsbereich 320 "Herzfunktion und ihre Regulation."The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger These authors contributed equally to this work.

§ To whom correspondence should be addressed. Tel.: 011-49-6221-568855; Fax: 011-49-6221-565515; E-mail: johannkiehn@ukl.uniheidelberg.de.

    ABBREVIATIONS

The abbreviations used are: IKr, delayed rectifier potassium current; HERG, human ether-a-go-go-related gene; PKA, cyclic AMP-dependent protein kinase; PDE IV, cAMP-specific phosphodiesterase; PMA, phorbol 12-myristate 13-acetate; WT, wild type.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Carmeliet, E. (1993) Eur. Heart J. 14 Suppl. H, 3-13
2. Warmke, J. E., and Ganetzky, B. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 3438-3442[Abstract/Free Full Text]
3. Sanguinetti, M. C., Changan, J., Curran, M. E., and Keating, M. T. (1995) Cell 81, 1-20[CrossRef][Medline] [Order article via Infotrieve]
4. Trudeau, M. C., Warmke, J. W., Ganetzky, B., and Robertson, G. A. (1995) Science 269, 92-95[Abstract/Free Full Text]
5. Kiehn, J., Lacerda, A. E., Wible, B., and Brown, A. M. (1996) Circulation 94, 2572-2579[Medline] [Order article via Infotrieve]
6. Spector, P. S., Curran, M. E., Keating, M. T., and Sanguinetti, M. C. (1996) Circ. Res. 78, 499-503[Abstract/Free Full Text]
7. Kiehn, J., Thomas, D., Karle, C. A., Schöls, W., and Kübler, W. (1999) Naunyn-Schmiedeberg's Arch. Pharmacol. 359, 212-219[CrossRef][Medline] [Order article via Infotrieve]
8. Sanguinetti, M. C., Curran, M. E., Spector, P. S., and Keating, M. T. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 2208-2212[Abstract/Free Full Text]
9. Roden, D. M., Lazzara, R., Rosen, M., Schwartz, P. J., Towbin, J., and Vincent, G. M. (1996) Circulation 94, 1996-2012[Medline] [Order article via Infotrieve]
10. Walsh, K. B., and Kass, R. S. (1988) Science 242, 67-69[Abstract/Free Full Text]
11. Seamon, K. B., Padgett, W., and Daly, J. W. (1981) Proc. Natl. Acad. Sci. U. S. A. 78, 3363-3367[Abstract/Free Full Text]
12. Beavo, J. A. (1998) Adv. Second Messenger Phosphoprotein Res. 22, 1-38
13. Kiehn, J., Karle, C., Thomas, D., Yao, X., Brachmann, J., and Kübler, W. (1998) J. Biol. Chem. 273, 25285-25291[Abstract/Free Full Text]
14. Sanguinetti, M. C., and Jurkiewicz, N. K. (1990) J. Gen. Physiol. 96, 195-215[Abstract/Free Full Text]
15. Palma, E., Yu, Z., Fishman, G. I., and McDonald, T. V. (1998) Circulation 98 Suppl. I, 57
16. Darbon, J. M., Valette, A., and Bayard, F. (1986) Biochem. Pharmacol. 35, 2683-2686[CrossRef][Medline] [Order article via Infotrieve]
17. Sun, Z. H., Swan, H., Viitasalo, M., and Toivonen, L. (1998) J. Am. Coll. Cardiol. 31, 1400-1405[Abstract/Free Full Text]
18. Kang, J. X., and Leaf, A. (1995) Biochem. Biophys. Res. Commun. 208, 629-636[CrossRef][Medline] [Order article via Infotrieve]
19. Lerman, B. B., Belardinelli, L., West, G. A., Berne, R. M., and DiMarco, J. P. (1986) Circulation 74, 270-280[Medline] [Order article via Infotrieve]
20. Hsu, C., Yang, S. L., Hsu, S. P., Hsu, H. K., and Liu, M. S. (1997) J. Surg. Res. 71, 161-165[CrossRef][Medline] [Order article via Infotrieve]
21. Bender, J. S. (1996) Am. Surg. 62, 73-75[Medline] [Order article via Infotrieve]
22. Yang, S. L., Hsu, C., Lue, S. I., Hsu, H. K., and Liu, M. S. (1997) Shock 8, 68-72[Medline] [Order article via Infotrieve]
23. Varriale, P., and Ramaprasad, S. (1995) J. Electrocardiol. 28, 327-329[CrossRef][Medline] [Order article via Infotrieve]
24. Saman, S., Coetzee, W. A., and Opie, L. H. (1988) J. Mol. Cell. Cardiol. 20, 91-95[CrossRef][Medline] [Order article via Infotrieve]
25. Priori, S. G., Napolitano, C., Paganini, V., Cantu, F., and Schwartz, P. J. (1997) PACE 20, 2052-2057
26. Zhou, J. T., Zheng, L. R., and Liu, W. Y. (1992) PACE 15, 2164-2168
27. Naccarelli, G. V., and Goldstein, R. A. (1989) Am. J. Cardiol. 63, 35A-40A[CrossRef][Medline] [Order article via Infotrieve]
28. Packer, M. (1989) Am. J. Cardiol. 63, 41A-45A[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.



This article has been cited by other articles:


Home page
J. Physiol.Home page
S. L. Cockerill, A. B. Tobin, I. Torrecilla, G. B. Willars, N. B. Standen, and J. S. Mitcheson
Modulation of hERG potassium currents in HEK-293 cells by protein kinase C. Evidence for direct phosphorylation of pore forming subunits
J. Physiol., June 1, 2007; 581(2): 479 - 493.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
S. Y. M. Yeung and I. A. Greenwood
Pharmacological and biophysical isolation of K+ currents encoded by ether-a-go-go-related genes in murine hepatic portal vein smooth muscle cells
Am J Physiol Cell Physiol, January 1, 2007; 292(1): C468 - C476.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
C.-u. Choe, E. Schulze-Bahr, A. Neu, J. Xu, Z. I. Zhu, K. Sauter, R. Bahring, S. Priori, P. Guicheney, G. Monnig, et al.
C-terminal HERG (LQT2) mutations disrupt IKr channel regulation through 14-3-3{epsilon}
Hum. Mol. Genet., October 1, 2006; 15(19): 2888 - 2902.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. N. Obreztchikova, K. W. Patberg, A. N. Plotnikov, N. Ozgen, I. N. Shlapakova, A. V. Rybin, E. A. Sosunov, P. Danilo Jr., E. P. Anyukhovsky, R. B. Robinson, et al.
IKr contributes to the altered ventricular repolarization that determines long-term cardiac memory
Cardiovasc Res, July 1, 2006; 71(1): 88 - 96.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. Allouis, F. Le Bouffant, R. Wilders, D. Peroz, J.-J. Schott, J. Noireaud, H. Le Marec, J. Merot, D. Escande, and I. Baro
14-3-3 Is a Regulator of the Cardiac Voltage-Gated Sodium Channel Nav1.5
Circ. Res., June 23, 2006; 98(12): 1538 - 1546.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Gentile, T. Darden, C. Erxleben, C. Romeo, A. Russo, N. Martin, S. Rossie, and D. L. Armstrong
Rac GTPase signaling through the PP5 protein phosphatase
PNAS, March 28, 2006; 103(13): 5202 - 5206.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. Zhou, C. E. Augelli-Szafran, J. A. Bradley, X. Chen, B. J. Koci, W. A. Volberg, Z. Sun, and J. S. Cordes
Novel Potent Human Ether-a-Go-Go-Related Gene (hERG) Potassium Channel Enhancers and Their in Vitro Antiarrhythmic Activity
Mol. Pharmacol., September 1, 2005; 68(3): 876 - 884.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. Thomas, A.-B. Wimmer, C. A. Karle, M. Licka, M. Alter, M. Khalil, H. E. Ulmer, S. Kathofer, J. Kiehn, H. A. Katus, et al.
Dominant-negative IKs suppression by KCNQ1-{Delta}F339 potassium channels linked to Romano-Ward syndrome
Cardiovasc Res, August 15, 2005; 67(3): 487 - 497.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. Thomas, B. C. Hammerling, A.-B. Wimmer, K. Wu, E. Ficker, Y. A. Kuryshev, D. Scherer, J. Kiehn, H. A. Katus, W. Schoels, et al.
Direct block of hERG potassium channels by the protein kinase C inhibitor bisindolylmaleimide I (GF109203X)
Cardiovasc Res, December 1, 2004; 64(3): 467 - 476.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J.-S. Bian, A. Kagan, and T. V. McDonald
Molecular analysis of PIP2 regulation of HERG and IKr
Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H2154 - H2163.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
W. Hirdes, L. F. Horowitz, and B. Hille
Muscarinic modulation of erg potassium current
J. Physiol., August 15, 2004; 559(1): 67 - 84.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. J Paavonen, H. Chapman, P. J Laitinen, H. Fodstad, K. Piippo, H. Swan, L. Toivonen, M. Viitasalo, K. Kontula, and M. Pasternack
Functional characterization of the common amino acid 897 polymorphism of the cardiac potassium channel KCNH2 (HERG)
Cardiovasc Res, September 1, 2003; 59(3): 603 - 611.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. Thomas, W. Zhang, K. Wu, A.-B. Wimmer, B. Gut, G. Wendt-Nordahl, S. Kathofer, V. A.W. Kreye, H. A. Katus, W. Schoels, et al.
Regulation of HERG potassium channel activation by protein kinase C independent of direct phosphorylation of the channel protein
Cardiovasc Res, July 1, 2003; 59(1): 14 - 26.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
A. CHERUBINI, S. PILLOZZI, G. HOFMANN, O. CROCIANI, L. GUASTI, E. LASTRAIOLI, S. POLVANI, A. MASI, A. BECCHETTI, E. WANKE, et al.
HERG K+ Channels and {beta}1 Integrins Interact through the Assembly of a Macromolecular Complex
Ann. N.Y. Acad. Sci., November 1, 2002; 973(1): 559 - 561.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. S. Cayabyab and L. C. Schlichter
Regulation of an ERG K+ Current by Src Tyrosine Kinase
J. Biol. Chem., April 12, 2002; 277(16): 13673 - 13681.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. Thomas, B. Gut, G. Wendt-Nordahl, and J. Kiehn
The Antidepressant Drug Fluoxetine Is an Inhibitor of Human Ether-A-Go-Go-Related Gene (HERG) Potassium Channels
J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 543 - 548.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
C. A Karle, E. Zitron, W. Zhang, S. Kathofer, W. Schoels, and J. Kiehn
Rapid component IKr of the guinea-pig cardiac delayed rectifier K+ current is inhibited by {beta}1-adrenoreceptor activation, via cAMP/protein kinase A-dependent pathways
Cardiovasc Res, February 1, 2002; 53(2): 355 - 362.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
C. A Karle and J. Kiehn
An ion channel 'addicted' to ether, alcohol and cocaine: the HERG potassium channel
Cardiovasc Res, January 1, 2002; 53(1): 6 - 8.
[Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. Thomas, G. Wendt-Nordahl, K. Röckl, E. Ficker, A. M. Brown, and J. Kiehn
High-Affinity Blockade of Human Ether-A-Go-Go-Related Gene Human Cardiac Potassium Channels by the Novel Antiarrhythmic Drug BRL-32872
J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 753 - 761.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
J. Bérubé, D. Caouette, and P. Daleau
Hydrogen Peroxide Modifies the Kinetics of HERG Channel Expressed in a Mammalian Cell Line
J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 96 - 102.
[Abstract] [Full Text]


Home page
J. Neurophysiol.Home page
J. W. Y. Chen and R. A. Eatock
Major Potassium Conductance in Type I Hair Cells From Rat Semicircular Canals: Characterization and Modulation by Nitric Oxide
J Neurophysiol, July 1, 2000; 84(1): 139 - 151.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Cui, A. Kagan, D. Qin, J. Mathew, Y. F. Melman, and T. V. McDonald
Analysis of the Cyclic Nucleotide Binding Domain of the HERG Potassium Channel and Interactions with KCNE2
J. Biol. Chem., May 11, 2001; 276(20): 17244 - 17251.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. Bian, J. Cui, and T. V. McDonald
HERG K+ Channel Activity Is Regulated by Changes in Phosphatidyl Inositol 4,5-Bisphosphate
Circ. Res., December 7, 2001; 89(12): 1168 - 1176.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow